Bristol-myers Squibb

This phase 2 trial tested whether adding relatlimab to the standard immunotherapy nivolumab plus chemotherapy could shrink tumors better in people with advanced or recurrent non-small cell lung cancer. About 468 participants received either the two-immunotherapy combo with chemo …

This study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. The trial involved 135 newly diagnosed patients. Researchers measured saf…

This phase 3 trial compared a combination of two immunotherapy drugs (nivolumab and ipilimumab) against the standard drug sunitinib in over 1,000 people with untreated advanced or metastatic kidney cancer. The study measured how well the tumors shrank, how long patients lived wit…

This early-phase study tested a new drug called BMS-986326 in 45 adults with different forms of lupus, including skin and systemic lupus. The main goal was to check safety and how the body processes the drug, not yet to see if it works. Participants received either the drug or a …

This study looked at 88 adults in China with lower-risk myelodysplastic syndromes (MDS) who had not received prior treatment with erythropoiesis-stimulating agents. They were given luspatercept, and researchers tracked how many became free from red blood cell transfusions and whe…

This study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monit…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This completed Phase 2 trial tested the long-term safety of deucravacitinib (BMS-986165), a daily pill, in 261 people with systemic lupus erythematosus (SLE). Participants had already completed an earlier study and continued taking the drug to monitor side effects and lab abnorma…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This study looked at the long-term safety of the drug mavacamten in adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. About 314 people who had already finished earlier studies took part. The goal was to track side effects over time, not to cure…

This phase 3 trial tested whether adding immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with advanced esophageal cancer live longer or keep their cancer from growing. About 970 participants with inoperable or metastatic esophageal squamous ce…

This Phase 2 trial tested an experimental drug called BMS-986278 in 403 adults with pulmonary fibrosis, a condition that causes lung scarring and breathing difficulty. The study compared the drug to a placebo to see if it could improve lung function and was safe. Results will hel…

This study tested the immunotherapy drug nivolumab (Opdivo) combined with one of three other drugs (rucaparib, docetaxel, or enzalutamide) in 292 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to see if these combinations…

This study tested a drug called mavacamten in 38 Japanese adults with a condition where the heart muscle is too thick, making it hard for the heart to pump blood. The goal was to see if the drug could improve heart function and symptoms over 30 weeks. Participants took the drug a…

This study tested whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard chemotherapy for Chinese patients with advanced pleural mesothelioma, a rare cancer of the lung lining. 102 patients who could not have surgery were randomly a…

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This study tested whether adding a third drug (relatlimab) to a two-drug combination (nivolumab and bevacizumab) is safe and works better for people with advanced liver cancer who haven't had treatment before. The 83 participants received either the three-drug combo or the two-dr…

This study tested a combination of two drugs, relatlimab and nivolumab, in 266 adults with advanced liver cancer who had not received immunotherapy before but whose cancer worsened after other treatments. The goal was to see if the combination could shrink tumors or control the d…

This phase 3 trial tested whether adding the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy) to standard chemotherapy could improve outcomes for people with early-stage non-small cell lung cancer that can be surgically removed. The study enrolled 505 participants a…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced liver cancer that could not be treated with surgery. The goal was to see if these drugs could shrink tumors and control the disease. The trial included 657 adults and found that the treat…

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and ipilimumab, could shrink tumors or slow progression in men with metastatic castration-resistant prostate cancer. 351 participants received either the combination, ipilimumab alone, or the chemother…

This early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …

This phase 3 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 719 patients who had not received prior treatment took part. The study compared the combin…

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This study tested a combination of nivolumab (Opdivo) and trametinib (Mekinist), with or without ipilimumab (Yervoy), in 325 people whose colorectal cancer had spread and had not responded to prior treatments. The main goals were to check safety and see if the drugs could shrink …

This study looked at 115 Canadian adults with obstructive hypertrophic cardiomyopathy (oHCM) who started taking mavacamten as part of routine care. Researchers reviewed patient charts to see if the drug improved heart function and symptoms. The goal was to understand how mavacamt…

This phase 2 trial tested an experimental drug called BMS-986322 in 109 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could significantly reduce psoriasis skin symptoms (measu…

This study tested whether the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back after surgery. About 794 people who had surgery for stage II or III cancer of the esophagus or gastroesophageal junction received either nivolumab or a placebo. The main…

This study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested whether the immunotherapy drug nivolumab, alone or with other drugs, can shrink tumors in people with colon cancer that has returned or spread. It included 385 participants whose tumors had a specific genetic feature called MSI-H or were non-MSI-H. The goal was …

This study tested whether combining the immunotherapy drug nivolumab with another drug (ipilimumab) or with standard chemotherapy could help people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 2,700 patients who had not received pr…

This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The main goal was to see if more people achieved clear or almost clear scalp skin after 16 weeks of treatment. This is a disease-control study, mea…

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumu…

This study tested an experimental drug called BMS-813160, given together with chemotherapy or the immunotherapy nivolumab (Opdivo), in 332 people with advanced colorectal or pancreatic cancer. The main goals were to check safety, side effects, and how the body processes the drug,…

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now comple…

This study looked at 163 patients with obstructive hypertrophic cardiomyopathy who were prescribed mavacamten at a single US hospital. Researchers collected information on symptoms, heart function, and patient characteristics from medical records. The goal was to see how the drug…

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) in Germany who were already prescribed ozanimod (Zeposia). Over three years, researchers collected data on how long patients stayed on the drug, its effect on quality of life, and any side effects. …

This study tested whether the drug deucravacitinib can improve quality of life for adults with moderate-to-severe plaque psoriasis. 180 participants received either the drug or a placebo. The main goal was to see if more people on the drug reported no or minimal impact of their s…

This early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Rese…

This Phase 3 study tested the drug mavacamten in 580 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart muscle condition that makes it harder for the heart to pump blood. Participants received either mavacamten or a placebo. The study measured changes in…

This study looked at how well a combination of nivolumab (an immunotherapy drug) and chemotherapy works for people with advanced or recurrent stomach cancer who haven't had treatment before. It involved 500 patients in Japan and tracked things like how long the cancer stayed unde…

This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…

This study reviewed information from 683 adults with obstructive hypertrophic cardiomyopathy who took mavacamten through a support program in Canada. Researchers looked at patient characteristics and how long they stayed on the medication. The goal was to understand real-world us…

This completed study reviewed medical records of 200 adults with cancer who received the drug nivolumab (Opdivo) either as an intravenous infusion or as a subcutaneous injection (Opdivo Qvantig) in community oncology clinics across the United States. The goal was to describe the …

This study watched 152 melanoma patients who had their tumors surgically removed and then started nivolumab as part of their normal care. Researchers tracked how long patients stayed cancer-free, whether the cancer spread, and overall survival. The goal was to see how well the dr…

This study looked at 636 older Italian patients with a type of irregular heartbeat called non-valvular atrial fibrillation (NVAF). Researchers wanted to understand why some patients start taking blood thinners and others do not, and how long they stay on their treatment. The goal…

This study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over tim…

This completed study in Japan looked at how low-risk myelodysplastic syndrome (MDS) or unexplained anemia affects patients' daily lives. Researchers used questionnaires and interviews with 56 participants to understand symptoms, quality of life, and unmet needs. The goal was to c…

This study looked at whether taking the acid-reducing medicine famotidine changes how the body processes a new drug called afimetoran. It involved 32 healthy adults and used a crossover design to compare drug levels with and without famotidine. The goal was to gather safety and d…

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked…

This completed Phase 1 study looked at how the cancer drug repotrectinib changes the levels of other medications in the body. Thirty healthy adults took repotrectinib along with several common drugs (metformin, digoxin, rosuvastatin, bupropion, flurbiprofen, and omeprazole). The …

This study looked back at medical records of 418 patients with lower-risk myelodysplastic syndromes (MDS) who had not previously used erythropoiesis-stimulating agents (ESAs). Researchers examined how luspatercept was used in everyday practice, including dosing, treatment changes…

This completed study collected real-world data from 112 adults in France with acute myeloid leukemia (AML) who were in remission and taking oral azacitidine as maintenance therapy. The goal was to describe patient characteristics, treatment patterns, and outcomes like relapse and…

This completed Phase 1 study tested an experimental drug called BMS-986460 in 85 healthy adult men. The goal was to see how safe different pill versions are and how the body processes them. No treatment was given for any disease—this was purely an early safety and drug-level stud…

This French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…

This study looked at how taking the drug Admilparant with or without food changes the amount of drug in the blood. Fifty-six healthy adults took the tablet in two different conditions. The results will help doctors know whether to take this medicine with meals.

This completed study from Argentina looked at 70 patients with resectable non-small cell lung cancer who received nivolumab (Opdivo) plus chemotherapy before surgery. Researchers wanted to see how well this combination works in real-world practice, measuring how many patients had…

This study looked at real-world data from over 140,000 people in Sweden with rheumatoid arthritis or psoriatic arthritis. Researchers tracked how many people developed different types of cancer while taking abatacept or other arthritis drugs. The goal was to better understand the…

This completed study looked at the safety of the arthritis drug abatacept in over 38,000 people with rheumatoid or psoriatic arthritis in Denmark. Researchers used a national health registry to track rates of cancers and other side effects. The goal was to better understand the d…

This study looked at how 177 people with lower-risk myelodysplastic syndromes (MDS) are treated in real-world clinics across Japan. Researchers collected data on treatments, blood transfusions, and healthcare costs to understand current practice patterns. The goal was to describe…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …

This completed Phase 4 study looked at how much deucravacitinib (SOTYKTU®), a drug for plaque psoriasis, passes into breast milk. Eight healthy lactating women took a single dose, and researchers measured drug levels in their milk and blood. The goal was to estimate how much of t…

This study looked at 535 people in France with advanced non-small cell lung cancer who were given nivolumab after at least one round of chemotherapy. Researchers wanted to see how well the drug worked, how long it kept cancer from getting worse, and what side effects occurred in …

This study looked at 212 adults with advanced non-small cell lung cancer who received the drug nivolumab after chemotherapy. Researchers tracked how many patients were still alive 12, 24, and 36 months after starting treatment. The goal was to see how well the drug works in every…

This early-stage study tested a new drug called BMS-986419 in 74 healthy volunteers to see if it is safe and how the body processes it. The study also checked if the drug affects the heart's electrical activity. Since participants were healthy, the goal was only to gather safety …

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient charac…

This completed study looked at 327 adults with advanced kidney cancer who received one of two drug combinations (nivolumab+ipilimumab or pembrolizumab+lenvatinib) in real-world U.S. clinics. Researchers collected data on patient characteristics, treatment patterns, and outcomes f…

This study looked at how the drug BMS-986278 behaves in people with normal kidneys, severe kidney disease, or kidney failure on dialysis. 27 adults took a single dose to measure drug levels and check for side effects. The goal was to gather safety information, not to treat the di…

This completed Phase 1 trial tested the safety, tolerability, and heart effects of the drug BMS-986278 in 42 healthy adults. Participants received either the drug, a placebo, or a control medication to check for any impact on heart rhythm. The study aims to ensure the drug is saf…

This study looked at how a single dose of the drug repotrectinib stays in the blood of people with moderate or severe liver impairment compared to healthy volunteers. 18 adults took part to help understand if liver problems change drug levels. The results will guide dosing for pa…

This study tested a single dose of an experimental drug called BMS-986446 in 46 healthy adults. The goal was to measure how the drug moves through the body and how well it is tolerated when given as a shot under the skin. The results will help design future studies for people wit…

This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their disease-modifying therapy to ozanimod. Researchers tracked why they switched (e.g., lack of effectiveness, side effects) and how the switch was done. The goal was to understand r…